Janssen Vaccines and Prevention’s corporate headquarters and main Research & Development facilities are in Leiden, The Netherlands and currently employs about 1000 people. Janssen Vaccines and Prevention is part of Janssen Pharmaceuticals, of the Johnson & Johnson family of companies and is a fully integrated biopharmaceutical company that focuses on the development, production and sales of biopharmaceuticals aimed at preventing infectious diseases. One of the focus points of Janssen Vaccines is the prevention of respiratory infections with RSV and influenza next to prevention of HIV and global emerging diseases like Ebola. Viral vaccine discovery and translational medical research at Janssen is mainly located in Leiden with an international staff of around 100 employees with a network of commercial and academic partners.
Dr R. Zahn has a major research interest in the immunological response to viral infections, and its prevention by vaccination, and to develop discovery insights into clinical development. He is head of the non-clinical immunology research for viral vaccines and has established a deep knowledge in viral vaccine vector immunology.